

Novel uridine glycoconjugates, derivatives of 4-aminophenyl 1-thioglycosides, as potential antiviral compounds

Ewelina Krol^{1*}, Gabriela Pastuch-Gawolek^{2,3*}, Binay Chaubey^{1,4}, Gabriela Brzuska¹, Karol Erfurt⁵, Boguslaw Szewczyk¹

¹Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland

²Silesian University of Technology, Faculty of Chemistry, Chair of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Krzywoustego 4, 44-100 Gliwice, Poland

³Biotechnology Center, Silesian University of Technology, Krzywoustego 8, 44-100 Gliwice, Poland

⁴Functional Genomics Lab., Centre for Advanced Study, Department of Botany, University of Calcutta, 35, Ballygunge Circular Road, 700019 Kolkata, India

⁵Silesian University of Technology, Faculty of Chemistry, Department of Chemical Organic Technology and Petrochemistry, Krzywoustego 4, 44-100 Gliwice, Poland

* ewelina@biotech.ug.gda.pl; gabriela.pastuch@polsl.pl

1. Spectra




Fig. S1: ¹H NMR spectrum of succinic acid mono-2',3'-O-isopropylidene-uridin-5'yl ester **1**.




Fig. S2: ^{13}C NMR spectrum of succinic acid mono-2',3'-O-isopropylidene-uridin-5'yl ester **1**.




Fig. S3: ¹H NMR spectrum of succinic acid mono-2',3'-di-*O*-*tert*-butyldimethylsilyl-uridin-5'-yl ester **2**.




Fig. S4: ¹³C NMR spectrum of succinic acid mono-2',3'-di-O-tert-butyldimethylsilyl-uridin-5'-yl ester **2**.




Fig. S5: ¹H NMR spectrum of 2',3'-O-isopropylideneuridine-5'-carboxylic acid **3**.




Fig. S6: ¹³C NMR spectrum of 2',3'-O-isopropylideneuridine-5'-carboxylic acid **3**.




Fig. S7: ¹H NMR spectrum of 2',3'-di-*O*-*tert*-butyldimethylsilyluridine-5'-carboxylic acid **4**.




Fig. S8: ^{13}C NMR spectrum of 2',3'-di-*O*-*tert*-butyldimethylsilyluridine-5'-carboxylic acid **4**.




Fig. S9: ¹H NMR spectrum of 4-aminophenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside **5**.




Fig. S10: ¹³C NMR spectrum of 4-aminophenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside **5**.




Fig. S11: ¹H NMR spectrum of 4-aminophenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside **6**.




Fig. S12: ¹³C NMR spectrum of 4-aminophenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside **6**.




Fig. S13: ^1H NMR spectrum of glycoconjugate **7**.




Fig. S14: ^{13}C NMR spectrum of glycoconjugate 7.




Fig. S15: ¹H NMR spectrum of glycoconjugate **8**.




Fig. S16: ¹³C NMR spectrum of glycoconjugate **8**.




Fig. S17: ^1H NMR spectrum of glycoconjugate **9**.




Fig. S18: ¹³C NMR spectrum of glycoconjugate **9**.




Fig. S19: ^1H NMR spectrum of glycoconjugate **10**.




Fig. S20: ^{13}C NMR spectrum of glycoconjugate **10**.




Fig. S21: ¹H NMR spectrum of glycoconjugate **11**.




Fig. S22: ¹³C NMR spectrum of glycoconjugate **11**.




Fig. S23: ^1H NMR spectrum of glycoconjugate **12**.




Fig. S24: ¹³C NMR spectrum of glycoconjugate **12**.




Fig. S25: ¹H NMR spectrum of glycoconjugate **13**.




Fig. S26: ^{13}C NMR spectrum of glycoconjugate **13**.




Fig. S27: ^1H NMR spectrum of glycoconjugate **14**.




Fig. S28: ^{13}C NMR spectrum of glycoconjugate **14**.




Fig. S29: ^1H NMR spectrum of glycoconjugate **15**.




Fig. S30: ¹³C NMR spectrum of glycoconjugate **15**.

2. Antiviral activity of Sofosbuvir on HCV infection.




Fig. S31. Huh7-J20 cells were pre-treated for 1 h and infected with cell culture infectious HCV in the presence of different concentrations of Sofosbuvir or DMSO as a control for 3 h. Then, the inoculum was removed and fresh medium without compound was added for 72 h (Model 1, white bars). Huh7-J20 cells were pre-treated for 1 h, infected with JFH-1 for 3 h in the presence of various concentrations of Sofosbuvir or DMSO and then incubated for 72 h with fresh medium with inhibitor or DMSO (Model 2, grey bars). Huh7-J20 cells were infected for 3 h with JFH-1 and then treated with various concentrations of Sofosbuvir or DMSO for 72 h (Model 3, black bars). All inhibitory effects were determined by measuring SEAP assay performed on infected cell medium. Errors bars represent the SD of the means for 3 experiments.